Esophageal adenocarcinoma: Treatment modalities in the era of targeted therapy

Digestive Diseases and Sciences

Volumn 55, Issue 12, 2010, Pages 3304-3314

  Mukherjee, Kaushik ^a   Chakravarthy, A Bapsi ^b   Goff, Laura W ^b   El Rifai, Wael ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cancer; Esophageal; Radiation; Surgery; Targets; Therapy

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; MK 0547; MLN 8237; OBLIMERSEN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VE 465; VORINOSTAT;

BILE DUCT CARCINOMA; BLADDER CANCER; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GALLBLADDER CANCER; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; SYSTEMATIC REVIEW; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BARRETT ESOPHAGUS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 78649332138     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1187-4     Document Type: Review

References (119)

1. H Pohl HG Welch 2005 The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence J Natl Cancer Inst 97 2 142 146 15657344
2. LM Brown SS Devesa WH Chow 2008 Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age J Natl Cancer Inst 100 16 1184 1187 18695138
3. SS Devesa WJ Blot JF Fraumeni Jr 1998 Changing patterns in the incidence of esophageal and gastric carcinoma in the United States Cancer 83 10 2049 2053 1:STN:280:DyaK1M%2FktlCjuw%3D%3D 9827707
4. RF Souza K Krishnan SJ Spechler 2008 Acid, bile, and CDX: the abcs of making Barrett's metaplasia Am J Physiol Gastrointest Liver Physiol 295 2 G211 G218 1:CAS:528:DC%2BD1cXhtVaktrjJ 18556417
5. HY Zhang SJ Spechler RF Souza 2009 Esophageal adenocarcinoma arising in Barrett esophagus Cancer Lett 275 2 170 177 1:CAS:528:DC%2BD1MXhsFOmu78%3D 18703277
6. J Lagergren R Bergstrom A Lindgren O Nyren 1999 Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma N Engl J Med 340 11 825 831 1:STN:280:DyaK1M7msFeitw%3D%3D 10080844
7. W El-Rifai HF Frierson Jr CA Moskaluk, et al. 2001 Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa Gastroenterology 121 3 592 598 1:STN:280:DC%2BD3MvnvFSmsA%3D%3D 11522743
8. OJ Lee R Schneider-Stock PA McChesney, et al. 2005 Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis Neoplasia 7 9 854 861 1:CAS:528:DC%2BD2MXhtlClurfO 16229808
9. DF Peng M Razvi H Chen, et al. 2009 DNA hypermethylation regulates the expression of members of the mu-class glutathione s-transferases and glutathione peroxidases in Barrett's adenocarcinoma Gut 58 1 5 15 1:CAS:528: DC%2BD1MXhs1SktL8%3D 18664505
10. D Kuester W El-Rifai D Peng, et al. 2009 Silencing of mgmt expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus Cancer Lett 275 1 117 126 1:CAS:528:DC%2BD1MXhtVeitbc%3D 19027227
11. DT McManus A Olaru SJ Meltzer 2004 Biomarkers of esophageal adenocarcinoma and Barrett's esophagus Cancer Res 64 5 1561 1569 1:CAS:528:DC%2BD2cXhslektLs%3D 14996709
12. F Sato Z Jin K Schulmann, et al. 2008 Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features PLoS One 3 4 e1890 18382671
13. JS Cooper MD Guo A Herskovic, et al. 1999 Chemo radiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (rtog 85-01). Radiation therapy oncology group JAMA 281 17 1623 1627 1:STN:280:DyaK1M3kvFagtw%3D%3D 10235156
14. TN Walsh N Noonan D Hollywood A Kelly N Keeling TP Hennessy 1996 A comparison of multimodal therapy and surgery for esophageal adenocarcinoma N Engl J Med 335 7 462 467 1:STN:280:DyaK283psF2juw%3D%3D 8672151
15. JE Tepper 2008 Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma? Gastrointest Cancer Res 2 4 Suppl S2 S5 19343142
16. JD Urschel H Vasan 2003 A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer Am J Surg 185 6 538 543 12781882
17. F Fiorica D Di Bona F Schepis, et al. 2004 Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis Gut 53 7 925 930 1:STN:280:DC%2BD2czitVCksA%3D%3D 15194636
18. GY Ku DH Ilson 2009 Preoperative therapy for esophageal cancer Gastroenterol Clin North Am 38 1 135 152 19327572 ix
19. Y Yonemura N Kojima T Kawamura, et al. 2008 Treatment results of adenocarcinoma of the gastroesophageal junction Hepatogastroenterology 55 82-83 475 481 18613391
20. PA Davis S Law J Wong 2003 Colonic interposition after esophagectomy for cancer Arch Surg 138 3 303 308 12611579
21. RC Connors BC Reuben LA Neumayer DA Bull 2007 Comparing outcomes after transthoracic and transhiatal esophagectomy: a 5-year prospective cohort of 17,395 patients J Am Coll Surg 205 6 735 740 18035255
22. AP Barbour NP Rizk M Gonen, et al. 2007 Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome Ann Surg 246 1 1 8 17592282
23. JM Muller H Erasmi M Stelzner U Zieren H Pichlmaier 1990 Surgical therapy of oesophageal carcinoma Br J Surg 77 8 845 857 1:STN:280:DyaK3czms1ymuw%3D%3D 2203505
24. JB Hulscher JW van Sandick AG de Boer, et al. 2002 Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus N Engl J Med 347 21 1662 1669 12444180
25. FH Ellis Jr GJ Heatley K Balogh 1997 Proposal for improved staging criteria for carcinoma of the esophagus and cardia Eur J Cardiothorac Surg 12 3 361 364 9332912 discussion 364-365
26. CD Wright JC Kucharczuk SM O'Brien JD Grab MS Allen 2009 Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons general thoracic surgery database risk adjustment model J Thorac Cardiovasc Surg 137 3 587 595 19258071 discussion 596
27. JM Ng 2008 Perioperative anesthetic management for esophagectomy Anesthesiol Clin 26 2 293 304 18456214 vi
28. MB Orringer B Marshall MD Iannettoni 2000 Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis J Thorac Cardiovasc Surg 119 2 277 288 1:STN:280:DC%2BD3c7hsFOnug%3D%3D 10649203
29. AC Chang H Ji NJ Birkmeyer MB Orringer JD Birkmeyer 2008 Outcomes after transhiatal and transthoracic esophagectomy for cancer Ann Thorac Surg 85 2 424 429 18222237
30. KM Chu SY Law M Fok J Wong 1997 A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma Am J Surg 174 3 320 324 1:STN:280:DyaK2svmsVehtw%3D%3D 9324146
31. C Rizzetto SR DeMeester JA Hagen CG Peyre JC Lipham TR DeMeester 2008 En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma J Thorac Cardiovasc Surg 135 6 1228 1236 1:STN:280:DC%2BD1czns1GisQ%3D%3D 18544359
32. HJ Stein M Feith BL Bruecher J Naehrig M Sarbia JR Siewert 2005 Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection Ann Surg 242 4 566 573 16192817 discussion 573-565
33. JJ Nigro JA Hagen TR DeMeester, et al. 1999 Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: Implications for therapy J Thorac Cardiovasc Surg 117 1 16 23 1:STN:280:DyaK1M7gt1GhsQ%3D%3D 9869753 discussion 23-15
34. TW Rice G Zuccaro Jr DJ Adelstein LA Rybicki EH Blackstone JR Goldblum 1998 Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status Ann Thorac Surg 65 3 787 792 1:STN:280:DyaK1c7os1Cntg%3D%3D 9527214
35. BH Burmeister BM Smithers V Gebski, et al. 2005 Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial Lancet Oncol 6 9 659 668 16129366
36. D Cunningham WH Allum SP Stenning, et al. 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 1 11 20 1:CAS:528:DC%2BD28Xms1Chsrw%3D 16822992
37. Medical Research Council Oesophageal Cancer Working Group 2002 Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial Lancet 359 9319 1727 1733
38. DP Kelsen R Ginsberg TF Pajak, et al. 1998 Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer N Engl J Med 339 27 1979 1984 1:STN:280:DyaK1M%2FnslCjsg%3D%3D 9869669
39. A Herskovic K Martz M al-Sarraf, et al. 1992 Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus N Engl J Med 326 24 1593 1598 1:STN:280:DyaK383mtFKkuw%3D%3D 1584260
40. M Wang XZ Gu WB Yin GJ Huang LJ Wang DW Zhang 1989 Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients Int J Radiat Oncol Biol Phys 16 2 325 327 1:CAS:528:DyaL1MXktV2mt7Y%3D 2646253
41. SJ Arnott W Duncan M Gignoux, et al. 1998 Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (oesophageal cancer collaborative group) Int J Radiat Oncol Biol Phys 41 3 579 583 1:STN:280:DyaK1c3pslKhug%3D%3D 9635705
42. K Nygaard S Hagen HS Hansen, et al. 1992 Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer World J Surg 16 6 1104 1109 1:STN:280: DyaK3s%2FovVyhsg%3D%3D 1455880 discussion 1110
43. B Launois D Delarue JP Campion M Kerbaol 1981 Preoperative radiotherapy for carcinoma of the esophagus Surg Gynecol Obstet 153 5 690 692 1:STN:280:DyaL38%2FktVWgsA%3D%3D 6794167
44. M Gignoux A Roussel B Paillot, et al. 1987 The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C World J Surg 11 4 426 432 1:STN:280:DyaL2szitFChuw%3D%3D 3630187
45. JI Geh SJ Bond SM Bentzen R Glynne-Jones 2006 Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response Radiother Oncol 78 3 236 244 1:CAS:528:DC%2BD28Xjs1Wnurc%3D 16545878
46. LR Henry M Goldberg W Scott, et al. 2006 Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report Ann Surg Oncol 13 2 214 220 16418887
47. T Ruhstaller L Widmer JC Schuller, et al. 2009 Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (sakk 75/02) Ann Oncol 20 9 1522 1528 1:STN:280:DC%2BD1MrnsVCquw%3D%3D 19465425
48. V Gebski B Burmeister BM Smithers K Foo J Zalcberg J Simes 2007 Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis Lancet Oncol 8 3 226 234 1:CAS:528: DC%2BD2sXisVCqs78%3D 17329193
49. HL Jin H Zhu TS Ling HJ Zhang RH Shi 2009 Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis World J Gastroenterol 15 47 5983 5991 20014464
50. Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2006;3CD001556.
51. JM Leers S Ayazi JA Hagen, et al. 2009 Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of n status J Am Coll Surg 208 4 553 556 19476789
52. S Christen-Zaech R Seshadri J Sundberg AS Paller LM Pachman 2008 Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis Arthritis Rheum 58 2 571 576 18240225
53. IB Weinstein AK Joe 2006 Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy Nat Clin Pract Oncol 3 8 448 457 1:CAS:528:DC%2BD28Xpt1OktL8%3D 16894390
54. SM Rothenberg JA Engelman S Le DJ Riese 2nd DA Haber J Settleman 2008 Modeling oncogene addiction using RNA interference Proc Natl Acad Sci U S A 105 34 12480 12484 1:CAS:528:DC%2BD1cXhtVKqsbbF 18711136
55. DW Felsher 2008 Tumor dormancy and oncogene addiction APMIS 116 7-8 629 637 1:CAS:528:DC%2BD1cXht1Cjsb%2FP 18834407
56. IB Weinstein A Joe 2008 Oncogene addiction Cancer Res 68 9 3077 3080 1:CAS:528:DC%2BD1cXltlSmtrk%3D 18451130 discussion 3080
57. DW Felsher 2008 Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 68 9 3081 3086 1:CAS:528:DC%2BD1cXltlSmtrc%3D 18451131 discussion 3086
58. B Herberger W Berger H Puhalla, et al. 2009 Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells Mol Cancer Ther 8 6 1547 1556 1:CAS:528:DC%2BD1MXntVKgsbY%3D 19509244
59. AM Rygiel F Milano FJ Ten Kate, et al. 2008 Gains and amplifications of c-myc, EGFR, and 20.Q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus Cancer Epidemiol Biomarkers Prev 17 6 1380 1385 1:CAS:528:DC%2BD1cXnsVKgt7g%3D 18559552
60. H Friess A Fukuda WH Tang, et al. 1999 Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbb-2 and c-erbb-3 World J Surg 23 10 1010 1018 1:STN:280:DyaK1MvksVWktg%3D%3D 10512940
61. NW Wilkinson JD Black E Roukhadze, et al. 2004 Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma J Gastrointest Surg 8 4 448 453 15120370
62. TA D'Amico DH Harpole Jr 2000 Molecular biology of esophageal cancer Chest Surg Clin N Am 10 3 451 469 10967750
63. J Mueller M Werner JR Siewert 2000 Malignant progression in Barrett's esophagus: pathology and molecular biology Recent Results Cancer Res 155 29 41 1:STN:280:DC%2BD3c7lslKhtw%3D%3D 10693236
64. F Wang R Liu SW Lee CM Sloss J Couget JC Cusack 2007 Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance Oncogene 26 14 2006 2016 1:CAS:528: DC%2BD2sXjsFSiuro%3D 17001310
65. KL Wang TT Wu IS Choi, et al. 2007 Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome Cancer 109 4 658 667 1:CAS:528:DC%2BD2sXis1Smt74%3D 17211865
66. MK Gibson SC Abraham TT Wu, et al. 2003 Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy Clin Cancer Res 9 17 6461 6468 1:CAS:528:DC%2BD3sXhtVSqurvP 14695149
67. JR Walters 2004 Cell and molecular biology of the small intestine: new insights into differentiation, growth and repair Curr Opin Gastroenterol 20 2 70 76 1:CAS:528:DC%2BD2cXivFGqs7o%3D 15703624
68. GM Groisman M Amar A Meir 2004 Expression of the intestinal marker CDX2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia Mod Pathol 17 10 1282 1288 1:CAS:528:DC%2BD2cXovFOqt78%3D 15167938
69. RV Lord J Brabender K Wickramasinghe, et al. 2005 Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma Surgery 138 5 924 931 16291394
70. NE Avissar L Toia Y Hu, et al. 2009 Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR) J Gastrointest Surg 13 2 212 222 18854960
71. EL Kwak J Jankowski SP Thayer, et al. 2006 Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas Clin Cancer Res 12 Pt 1 14 4283 4287
72. S Schneider K Uchida J Brabender, et al. 2005 Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer J Am Coll Surg 200 3 336 344 15737843
73. TJ Price NC Tebbutt CS Karapetis, et al. 2010 Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: report from the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 Clin Colorectal Cancer 9 1 8 14 1:CAS:528: DC%2BC3cXisVehsL0%3D 20100683
74. H Safran M Suntharalingam T Dipetrillo, et al. 2008 Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity Int J Radiat Oncol Biol Phys 70 2 391 395 1:CAS:528:DC%2BD1cXosVGnug%3D%3D 17980508
75. C Pinto F Di Fabio S Siena, et al. 2007 Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 3 510 517 1:STN:280:DC%2BD2s7hsVKjsA%3D%3D 17164226
76. AU Pande RV Iyer A Rani, et al. 2007 Epidermal growth factor receptor-directed therapy in esophageal cancer Oncology 73 5-6 281 289 1:CAS:528:DC%2BD1cXnsVCls70%3D 18477853
77. AP Sutter M Hopfner A Huether K Maaser H Scherubl 2006 Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer Int J Cancer 118 7 1814 1822 1:CAS:528:DC%2BD28XislKlsb4%3D 16217753
78. MC Dobelbower SM Russo KP Raisch, et al. 2006 Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study Anticancer Drugs 17 1 95 102 1:CAS:528:DC%2BD2MXht1Glt7zP 16317296
79. T Dragovich S McCoy CM Fenoglio-Preiser, et al. 2006 Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J Clin Oncol 24 30 4922 4927 1:CAS:528:DC%2BD28Xht1eiu73L 17050876
80. M Javle A Pande R Iyer, et al. 2008 Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response Am J Clin Oncol 31 4 329 334 1:CAS:528: DC%2BD1cXpvFKnsbY%3D 18845990
81. DR Ferry M Anderson K Beddard, et al. 2007 A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response Clin Cancer Res 13 19 5869 5875 1:CAS:528:DC%2BD2sXhtFSntLvP 17908981
82. KA Cengel KR Voong S Chandrasekaran, et al. 2007 Oncogenic K-ras signals through epidermal growth factor receptor and wild-type H-ras to promote radiation survival in pancreatic and colorectal carcinoma cells Neoplasia 9 4 341 348 1:CAS:528:DC%2BD2sXkvVWgsrw%3D 17460778
83. A Uchida S Hirano H Kitao, et al. 2007 Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation Cancer Sci 98 3 357 363 1:CAS:528:DC%2BD2sXis1amtLw%3D 17270025
84. RV Lord R O'Grady C Sheehan AF Field RL Ward 2000 K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction J Gastroenterol Hepatol 15 7 730 736 1:CAS:528:DC%2BD3cXlvFWntb4%3D 10937677
85. G Burnat T Rau E Elshimi EG Hahn PC Konturek 2007 Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line Scand J Gastroenterol 42 12 1460 1465 1:CAS:528:DC%2BD2sXht1ynu7vK 17852856
86. D Vallbohmer JH Peters H Kuramochi, et al. 2006 Molecular determinants in targeted therapy for esophageal adenocarcinoma Arch Surg 141 5 476 481 1:CAS:528:DC%2BD28Xlt1SlsLo%3D 16702519 discussion 481-472
87. R Zhai G Liu K Asomaning, et al. 2008 Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk Carcinogenesis 29 12 2330 2334 1:CAS:528:DC%2BD1cXhsVOgsLfN 18780893
88. A Driessen W Landuyt S Pastorekova, et al. 2006 Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas Ann Surg 243 3 334 340 16495697
89. MA Shah RK Ramanathan DH Ilson, et al. 2006 Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 33 5201 5206 1:CAS:528:DC%2BD28XhtlemurbM 17114652
90. A Kleespies M Guba KW Jauch CJ Bruns 2004 Vascular endothelial growth factor in esophageal cancer J Surg Oncol 87 2 95 104 1:CAS:528: DC%2BD2cXns1Ghtrk%3D 15282704
91. N Maqani A Belkhiri C Moskaluk S Knuutila AA Dar W El-Rifai 2006 Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas Mol Cancer Res 4 7 449 455 1:CAS:528:DC%2BD28XmvFGku70%3D 16849520
92. PS Dahlberg BA Jacobson G Dahal, et al. 2004 ERBB2 amplifications in esophageal adenocarcinoma Ann Thorac Surg 78 5 1790 1800 15511476
93. A Walch K Specht H Braselmann, et al. 2004 Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma Int J Cancer 112 5 747 753 1:CAS:528:DC%2BD2cXpslKru7Y%3D 15386389
94. M al-Kasspooles JH Moore MB Orringer DG Beer 1993 Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas Int J Cancer 54 2 213 219 1:STN:280:DyaK3s3lt1CqtA%3D%3D 8098013
95. U Reichelt P Duesedau M Tsourlakis, et al. 2007 Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus Mod Pathol 20 1 120 129 1:CAS:528:DC%2BD28XhtlaktrnL 17143264
96. E Rossi V Villanacci G Bassotti, et al. 2006 Her-2/neu in Barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization Diagn Mol Pathol 15 3 125 130 1:CAS:528:DC%2BD28XhtVWnt7zP 16932066
97. TP Brien RD Odze CE Sheehan BJ McKenna JS Ross 2000 HER-2/neu gene amplification by fish predicts poor survival in Barrett's esophagus-associated adenocarcinoma Hum Pathol 31 1 35 39 1:CAS:528:DC%2BD3cXptVegtA%3D%3D 10665910
98. W El-Rifai MF Smith Jr G Li, et al. 2002 Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP Cancer Res 62 14 4061 4064 1:CAS:528:DC%2BD38XlsV2lsb0%3D 12124342
99. A Belkhiri A Zaika N Pidkovka S Knuutila C Moskaluk W El-Rifai 2005 DARPP-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas Cancer Res 65 15 6583 6592 1:CAS:528:DC%2BD2MXmvFSltrg%3D 16061638
100. A Belkhiri AA Dar DF Peng, et al. 2008 Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells Clin Cancer Res 14 14 4564 4571 1:CAS:528:DC%2BD1cXosFGitbw%3D 18579663
101. S Hamel A Bouchard C Ferrario, et al. 2009 Both t-DARPP and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers Breast Cancer Res Treat 120 47 57 19301121
102. S Sato Y Kajiyama M Sugano, et al. 2005 Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein Int J Radiat Oncol Biol Phys 61 1 203 211 1:CAS:528:DC%2BD2MXjsVCq 15629613
103. H Safran T Dipetrillo P Akerman, et al. 2007 Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma Int J Radiat Oncol Biol Phys 67 2 405 409 1:CAS:528:DC%2BD2sXntlentA%3D%3D 17097832
104. Van Cutsem E, Kang Y-K, Chung HC, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) (abstract from 2009 ASCO Annual Meeting). J Clin Oncol. 2009;27(18S), abstract no. LBA4507.
105. H Safran T DiPetrillo A Nadeem, et al. 2004 Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study Cancer Invest 22 5 670 677 1:CAS:528:DC%2BD2cXosFShsr4%3D 15581047
106. G Vader SM Lens 2008 The Aurora kinase family in cell division and cancer Biochim Biophys Acta 1786 1 60 72 1:CAS:528:DC%2BD1cXhtFCktrfE 18662747
107. PD Andrews 2005 Aurora kinases: shining lights on the therapeutic horizon? Oncogene 24 32 5005 5015 1:CAS:528:DC%2BD2MXmsFKqsrc%3D 16049526
108. R Giet D McLean S Descamps, et al. 2002 Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules J Cell Biol 156 3 437 451 1:CAS:528:DC%2BD38XhtVOqt7g%3D 11827981
109. RD Carvajal A Tse GK Schwartz 2006 Aurora kinases: new targets for cancer therapy Clin Cancer Res 12 23 6869 6875 1:CAS:528:DC%2BD28Xht1Kns7rK 17145803
110. H Zhou J Kuang L Zhong, et al. 1998 Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation Nat Genet 20 2 189 193 1:CAS:528:DyaK1cXms1eis78%3D 9771714
111. AA Dar A Zaika MB Piazuelo, et al. 2008 Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions Cancer 112 8 1688 1698 1:CAS:528:DC%2BD1cXls1Gkt74%3D 18311783
112. DG Cox SE Hankinson DJ Hunter 2006 Polymorphisms of the AURKA (STK15/Aurora kinase) gene and breast cancer risk (United States) Cancer Causes Control 17 1 81 83 16411056
113. J Chen D Li C Wei, et al. 2007 Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians Clin Cancer Res 13 10 3100 3104 1:CAS:528:DC%2BD2sXlt1KrtbY%3D 17505013
114. AA Dar A Belkhiri J Ecsedy A Zaika W El-Rifai 2008 Aurora kinase A inhibition leads to p73-dependent apoptosis in p53- deficient cancer cells Cancer Res 68 21 8998 9004 1:CAS:528:DC%2BD1cXhtlSkurzE 18974145
115. AA Dar A Belkhiri W El-Rifai 2008 The Aurora kinase A regulates GSK-3β in gastric cancer cells Oncogene 28 866 875 19060929
116. YG Lin A Immaneni WM Merritt, et al. 2008 Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth Clin Cancer Res 14 17 5437 5446 1:CAS:528:DC%2BD1cXhtVKmsbvF 18765535
117. ZZ Lin HC Hsu CH Hsu, et al. 2009 The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma J Hepatol 50 3 518 527 1:CAS:528:DC%2BD1MXhs1ektrk%3D 19155085
118. JJ Kitzen MJ de Jonge J Verweij 2009 Aurora kinase inhibitors Crit Rev Oncol Hematol 73 99 110 19369091
119. CH Cheung MS Coumar HP Hsieh JY Chang 2009 Aurora kinase inhibitors in preclinical and clinical testing Expert Opin Investig Drugs 18 4 379 398 1:CAS:528:DC%2BD1MXjvVWnsLo%3D 19335272